Myelin basic protein (MBP) or helper T cells reactive against MBP induce an autoimmune disease, experimental allergic encephalomyelitis, in B1O.PL and PL/J inbred mice. In both strains, virtually the entire repertoire of MBPspecific T cells recognize an N-terminal peptide fragment in the context of the I-AU molecule encoded by the major histocompatibility complex (MHC) and utilize a very limited set of T-cell receptor genes. To delineate the nature of the trimolecular complex, consisting of the T-cell receptor, MBP-peptide fragment, and MHC molecule (I-A'), we have synthesized 13 variants of the 9-mer N-terminal immunodominant peptide differing at residue 4 and studied their immune recognition in vitro and in vivo. These substitutions have a striking range of effects on T-cell activation, ability to bind to the MHC molecule, and initiation of immune responses in vivo. An understanding of the autoimmune peptide/MHC/T-cell receptor interactions allowed us to design variant 9-mer peptides that have high affinity for an MHC molecule and are effective in blocking experimental allergic encephalomyelitis, possibly through two distinct mechanisms, peripheral T-cell tolerance and the inhibition of binding of the encephalitogenic peptide to the MHC molecules.
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The immune system responds with enormous specificity to antigens through the elaboration of B and T cells and their specific receptors, immunoglobulins and T-cell receptors. Immunological recognition is mediated through the tripartite complex of T-cell receptor, peptide fragment, and major histocompatibility complex (MHC) molecule (1, 2) . Peptide fragments are generally presented to helper T cells by class II MHC molecules and to killer T cells by class I MHC molecules (3) . The x-ray structure of a human class I molecule suggests that the peptide is bound in a cleft with a floor of a ,-pleated sheet and walls of two a helices (4) . Homology considerations, modeling, and experimental studies suggest that class II molecules have a peptide-binding cleft similar to that of the class I molecule (5-7). T-cell accessory molecules, such as CD4 and CD8, appear to facilitate the activation of helper T cells (TH cells) and cytotoxic T cells (Tc cells), respectively, through additional interactions between the T cells and antigen-presenting cells (8, 9) . We are interested in understanding the role peptides play in T-cell immunological recognition and how this knowledge may be used to manipulate the immune response against autoantigens.
Experimental allergic encephalomyelitis (EAE), one of the best characterized T-cell-mediated autoimmune disease models, is induced after immunization with the myelin basic protein (MBP) or its peptide fragments (10) . EAE is mediated by CD4+ TH cells reactive against MBP in both B1O.PL and PL/J (H-2u) inbred mouse strains (11) . These TH cells are directed against the 9-mer N-terminal epitope of MBP and employ a limited number of a and , variable region (Va and V,8) gene segments (12, 13) . To define amino acid residues critical for interaction with the T-cell receptor, the I-Au molecule, or both, we have compared the effects on MBPspecific TH-cell activation of the wild-type N-terminal peptide [MBP-(1-9)] and a series of peptides containing one alanine substitution at each residue from position 1 through position 9 (14) . The lysine to alanine substitution at position 4 (16) and were purified on a reversed-phase column by HPLC.
Sequences for all peptides were confirmed after synthesis by either amino acid analysis or sequencing. MBP and peptides were dissolved in sterile saline and stored frozen. Culture Media. For lymph-node proliferation assays, serum-free Ventrex HL-1 medium (Ventrex Laboratories, Portland, ME), supplemented with 2 mM glutamine, penicillin (100 ,g/ml), and streptomycin (100 ,ug/ml) was used. T-cell hybridomas were grown in RPMI 1640 medium, supplemented with 10% (vol/vol) fetal calf serum, 2 mM glutamine, 1 mM sodium pyruvate, 50 ,uM 2-mercaptoethanol, penicillin (100,ug/ml), and streptomycin (100 ,g/ml).
IL-2 Release Assay. B10.PL TH cells derived from the 172.10 hybridoma specific for the MBP-(1-9) peptide (13) were incubated for 24-36 hr with serially diluted concentrations of the antigenic peptide in the presence of syngeneic antigen-presenting cells (-3000 rad-irradiated; 1 
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natants (100 gl) of these cultures were assayed for their concentration of IL-2 by their ability to support the growth of the IL-2-dependent T-cell line HT-2 (17 idues possessing side chains that are neutral or uncharged polar (glutamine or tyrosine) are more effective (10-to 500-fold) in T-cell activation than the wild type. Similarly, amino acid substitutions with side chains that are nonpolar or hydrophobic (alanine, leucine, isoleucine, valine, phenylalanine, or methionine) are even better (10-to 100-fold) than the neutral groups in stimulating T cells. Overall, the stimulatory capacity of the peptide MBP-(1-9) could be increased to '5000-fold with leucine, isoleucine, valine, or methionine substitutions at position 4. These data suggest that the side chain of position 4 of the MBP-(1-9) peptide fits into a hydrophobic pocket in the MHC or T-cell receptor molecule.
Interestingly, in contrast to the [Trp4]MBP-(1-9) peptide, the peptide [Arg4]MBP-(1-9) fails to activate the T cell (Fig. 1 ).
This may be due to the presence of a large positively charged guanidinium group that presumably does not fit effectively in this nonpolar pocket. The striking observation is that most substitutions are able to activate MBP-specific T 4 probably contacts the MHC molecule but not directly the T-cell receptor is further supported by the observation that the lymph node T cells from B1O.PL mice primed with either the MBP-(1-9) peptide or the variant peptides are cross-reactive with MBP-(1-9) and with each other in T-cell proliferation assays (Fig. 3) . In contrast, both the [Ala3]MBP-(1-9) (Fig. 4) molecule and to activate MBP-specific hybridoma T cells in vitro, it is a poor immunogen for PL/J mice in vivo (Fig. 4) Immunology: Kumar et al. I-Au -121,300 ± 1600 8/9
[Ala4]MBP-(1-9) Lymph-node proliferation assays were carried out simultaneously.
[3H]Thymidine incorporation without antigen ranged from 3700 to 8000 cpm.
Responses to purified protein derivative of tuberculin (PPD) served as control and ranged from 140,000 to 185,000 cpm in each case.
(ii) An alanine substitution at position 3 appears to eliminate effective interaction of the peptide with the T-cell receptor from MBP-specific T cells (14) and induce T-cell responses that are not encephalitogenic and different from MBP-(1-9) responses (Fig. 4) . We (1-9)}. These peptides appear to display even higher binding affinity for the I-AU molecule than the wild-type MBP-(1-9) peptide and inhibit TH-cell activation by stimulatory peptides in vitro (5-10 times less concentration of the doublesubstituted peptide required for 50% inhibition of the wildtype peptide) (ref. 14 and data not shown). Therefore, they should not stimulate encephalitogenic T cells in vivo and may compete effectively in vivo for binding (20) to I-AU and, therefore, be protective against EAE. When these peptides are coimmunized with the encephalitogenic MBP-(1-9) peptide, the development of EAE is significantly reduced in both PL/J and B1O.PL mice. This protection appears to be due to an in vivo competition for binding to the I-Au molecule because lymph-node proliferation responses to the MBP- (1) (2) (3) (4) (5) (6) (7) (8) (9) peptide are significantly suppressed in these mice ( Table 1 ). The modulation of the encephalitogenic MBP-(1-9)-reactive T cells appear specific, since coimmunization with the other encephalitogenic I-E-restricted epitope MBP-(31-50) still led to a high incidence of EAE. Clearly, 12 of the 13 variant peptides can activate T cells generally as well as or better than the native MBP-(1-9) peptide. Since the MHC molecule must accommodate a broad spectrum of peptides, it seems reasonable that this side chain diversity could be better accommodated by the MHC molecule than the T-cell receptor with its exquisite specificity. Consistent with this hypothesis, the only N-terminal variant peptide that cannot activate MBP-specific T cells also fails to bind to the I-AU molecule. Furthermore, the effective recognition of the MBP-(1-9) peptide by lymph-node T cells specific for the variant peptide suggests that the side chain of the amino acid residue at position 4 of the peptide MBP-(1-9) is oriented toward a hydrophobic pocket in the antigenbinding cleft of the I-AU molecule.
We also find that highly stimulatory variant peptides are less susceptible to the inhibition by anti-CD4 antibodies in vitro (unpublished data). Thus substitutions at position 4 appear to profoundly alter the trimolecular interactions in vitro and in vivo. Most notable is, however, the poor immunogenicity of [Ala4]MBP-(1-9) and its ability to prevent EAE in PL/J mice. The induces similar anergy or antigen-specific nonresponsiveness in disease-causing T cells that have high affinity for the MBP-(1-9) peptide or have high T-cell-receptor density.
Perhaps the lower-affinity T cells, presumably far less effective in inducing disease, are not tolerized and would give rise to the proliferative response to MBP-(1-9) after coimmunization. The ability to block immunologic recognition may be affected through the design of doubly substituted peptides 
